InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous system and autoimmune diseases, as outlined in a recent announcement.

The agreement integrates the Company’s validated AI platform and drug discovery capabilities with CMS’s extensive R&D resources and disease-area expertise. According to the announcement, InSilico Medicine anticipates R&D funding of several tens of millions of HKD for each of at least two co-development programs.

CMS, with stock codes 867.HK and 8A8.SGX, focuses on global first-in-class and best-in-class innovative pharmaceutical products and holds a strong track record in commercializing specialty therapeutics. InSilico Medicine, listed under the stock code 3696 on the Main Board of the Hong Kong Stock Exchange, is known for harnessing AI and automation technologies to accelerate drug discovery across multiple therapeutic areas.